Apogee Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-182.15	-83.99	-43.4
Depreciation & Amortization	0.19	-	-
Loss (Gain) From Sale of Investments	-12.24	-3.07	-
Stock-Based Compensation	23.33	6.1	2.34
Other Operating Activities	1.69	0.09	12.44
Change in Accounts Payable	-1.07	1.61	0.46
Change in Other Net Operating Assets	-0.93	4.49	10.25
Operating Cash Flow	-171.17	-74.76	-17.92
Capital Expenditures	-1.15	-0.17	-
Investment in Securities	-299.31	-273.74	-
Investing Cash Flow	-300.46	-273.91	-
Issuance of Common Stock	495.11	315.39	-
Other Financing Activities	-	-	-0.75
Financing Cash Flow	495.11	315.39	183.62
Net Cash Flow	23.47	-33.28	165.7
Free Cash Flow	-172.33	-74.93	-17.92
Free Cash Flow Per Share	-3.12	-3.00	-7.28
Levered Free Cash Flow	-113.42	-45.5	-
Unlevered Free Cash Flow	-113.42	-45.5	-
Change in Net Working Capital	0.24	-6.69	-

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q